This Must-Buy Biotech Firm Makes Over Double Pfizer’s Profits

Biotech is one of the hottest growing sectors on the markets right now, flush with cash and attracting a lot of big moves, like insider buying and M&As.

Of course, a lot of that has been driven by the success of the various mRNA COVID-19 vaccines. Pfizer Inc. (NYSE: PFE) reported a 27% profit margin at its last earnings report, and given the massive numbers of R&D projects in its pipeline, that growth is likely to continue even if COVID becomes endemic or fades away.

But there's another biotech firm that's blowing Pfizer completely out of the water, and I think every investor needs to get in on it now.

The tale of the tape here is staggering: 59% profit margin over the same period as Pfizer, $11.6 billion in operating cash flow over the trailing 12 months, $11 billion in revenue. A miniscule amount of debt compared to the piles of cash it's making.

Its stock is currently down a bit along with the rest of the market, which means we're at a prime entry point.

It's a no-brainer, folks. Check out this video for the ticker and two bonus trades...

The upside potential for biotech stocks is huge right now. But the most potentially lucrative investment I know of at the moment isn't a stock at all...

It's something I call "pre-IPO rights" - the right to claim shares in a company yet to go public. Often these rights can be had for a buck or less - the ones I'm thinking of, belonging to a crypto business, cost just $0.70 or so. But I've seen projections that hint these could rise to $7 over the next year.

In other words, an investor who put $100 in now could reap as much as $1,000 by the time it's all said and done. Here's how it could work...

Follow Money Morning onFacebook and Twitter.

About the Author

Shah Gilani boasts a financial pedigree unlike any other. He ran his first hedge fund in 1982 from his seat on the floor of the Chicago Board of Options Exchange. When options on the Standard & Poor's 100 began trading on March 11, 1983, Shah worked in "the pit" as a market maker.

The work he did laid the foundation for what would later become the VIX - to this day one of the most widely used indicators worldwide. After leaving Chicago to run the futures and options division of the British banking giant Lloyd's TSB, Shah moved up to Roosevelt & Cross Inc., an old-line New York boutique firm. There he originated and ran a packaged fixed-income trading desk, and established that company's "listed" and OTC trading desks.

Shah founded a second hedge fund in 1999, which he ran until 2003.

Shah's vast network of contacts includes the biggest players on Wall Street and in international finance. These contacts give him the real story - when others only get what the investment banks want them to see.

Today, as editor of Hyperdrive Portfolio, Shah presents his legion of subscribers with massive profit opportunities that result from paradigm shifts in the way we work, play, and live.

Shah is a frequent guest on CNBC, Forbes, and MarketWatch, and you can catch him every week on Fox Business's Varney & Co.

Read full bio